Диссертация (1091663), страница 15
Текст из файла (страница 15)
6 – 7.57)Stills H.F. Adjuvants and antibody production: dispelling the Mythsassociated with Freund‘s complete and other adjuvants. / Stills H.F. // ILAR Journal.– 2005. – Vol. 46. – No 3. – P. 280 – 293.58)https://www.seppic.com/montanide-isa-w-o59)Halassy B.
Effectiveness of novel PGM-containing incomplete Seppicadjuvants in rabbits. / Halassy B., Vdović V., Habjanec L., Balija M.L., Gebauer B.,Sabioncello A., Santek T., Tomasić J. // Vaccine. – 2007. – Vol. 25. – No 17. – P.3475 – 3481.60)Dupuis M. Immunization with the adjuvant MF59 induces macrophagetrafficking and apoptosis. / Dupuis M., Denis-Mize K., LaBarbara A., Peters W.,Charo I.F., McDonald D.M., Ott G. // European Journal of Immunology.
– 2001. –Vol. 31. – No 10. – P. 2910 – 2918.61)Seubert A. The adjuvants aluminum hydroxide and MF59 induce monocyteand granulocyte chemoattractants and enhance monocyte differentiation towarddendritic cells. / Seubert A., Monaci E., Pizza M.,O‘Hagan D.T., Wack A.
// Journalof Immunology. – 2008. – Vol. 180. – No 8. – P. 5402 – 5412.62)Wack A. Combinatio adjuvants for the induction of potent, long-lastingantibod and T-cell responses to influenza vaccine in mice. / Wack A., Baudner B.C.,Hilbert A.K., Manini I., Nuti S., Tavarini S., Scheffczik H., Ugozzoli M., Singh M.,Kazzaz J., Montomoli E., Del Giudice G., Rappuoli R., O'Hagan D.T.
// Vaccine. –2008. – Vol. 26. – No 4. – P. 552 – 561.9863)O‘Hagan D.T. The mechanism of action of MF59—an innately attractiveadjuvant formulation. / O‘Hagan D.T., Ott G.S., De Gregorio E., Seubert A. //Vaccine. – 2012. – Vol. 30. – No 29. – P. 4341 – 4348.64)Oreskovic Z. Oil-based adjuvants delivered intradermally induce highprimary IgG2 immune response in swine. / Oreskovic Z., Kudlackova H., Krejci J.,Nechvatalova K., Faldyna M. // Research in Veterinary Science.
– 2017. – Vol. 114.– P. 41 – 43.65)https://www.seppic.com/montanide-isa-o-w66)http://pfizerusa.naccvp.com/view_label.php?print=1&prodnum=100367)Bozkir A. Preparation and evaluation of multiple emulsions water-in-oil-in-water (W/O/W) as delivery system for influenza virus antigens. / Bozkir A., Hayta G.// Journal of Drug Targeting. – 2004. – Vol. 12.
– No. 3. – P. 157 – 164.68)Fukanoki S. Safety and efficacy of water-in-oil-in-water emulsion vaccinescontaining Newcastle disease virus haemagglutinin-neuraminidase glycoprotein. /Fukanoki S., Iwakura T., Iwaki S., Matsumoto K., Takeda R., Ikeda K., Shi Z., MoriH. // Avian Pathology: the journal of the W.V.P.A. – 2001. – Vol. 30. – No 5.
– P.509 – 516.69)Leclercq S.Y. Evaluation of water-in-oil-in-water multiple emulsion andmicroemulsion as potential adjuvants for immunization with rabies antigen. /Leclercq S.Y., dos Santos R.M.M., Macedo L.B., Campos P.C., Ferreira T.C., deAlmeida J.G., Seniuk J.G., Serakides R., Silva-Cunha A., Fialho S.L. // EuropeianJournal of Pharmacuetical Science. – 2011. – Vol. 43. – No 5. – P. 378 – 385.70)Bouguyon E. A new adjuvant combined with inactivated influenza enhancesspecific CD8 T cell response in mice and decreases symptoms in swine uponchallenge. / Bouguyon E., Goncalves E., Shevtsov A., Maisonnasse P., Remyga S.,Goryushev O., Deville S., Bertho N., Ben Arous J.
// Viral Immunology. – 2015. –Vol. 28. – No 9. – P. 524 – 531.71)Maree F.F. Intra-serotype SAT2 chimeric foot-and-mouth disease vaccineprotects cattle against FMDV challenge. / Maree F.F., Nsamba P., Mutowembwa P.,99Rotherham L.S., Esterhuysen J., Scott K. // Vaccine.
– 2015. – Vol. 33. – No 25. – P.2909 – 2916.72)Jansen T. Structure and oil type-based efficacy of emulsion adjuvants. /Jansen T., Hofmans M.P.M., Theelen M.J.G., Manders F. // Vaccine. – 2006. – Vol.24. – No 26. – P. 5400 – 5405.73)Oda K. Emulsifier content and side effects of oil-based adjuvant vaccine inswine. / Oda K., Tsukahara F., Kubota S., Kida K., Kitajama T., Hashimoto S. //Researsh in Veterinary Science.
– 2006. – Vol. 81. – No 1. – P. 51 – 57.74)Shah R.R. The development of self-emulsifying oil-in-water emulsionadjuvant and an evaluation of the impact of droplet size on performance. / Shah R.R.,Dodd S., Schaefer M., Ugozzoli M., Singh M., Otten G.R., Amiji M.M., O'HaganD.T., Brito L.A. // Journal of Pharmaceutical Science. – 2015. – Vol. 104. – No 4. –P. 1352 – 1361.75)Kensil C.R.
Saponins as vaccine adjuvants. / Kensil C.R. // Critical Reveiwsin Therapeutic Drug Carrier System. – 1996. – Vol. 13. No 1-2. – P. 1 – 55.76)EрeмeцВ.И.Испoльзoвaниeсaпoнинoвприкoнструирoвaниипрoтивoвирусных вaкцин. / Eрeмeц В.И., Сaмуйлeнкo A.Я., Eрeмeц Н.К.,Фoминa Г.A., Скичкo Н.Д. // Рaзрaбoткa и oсвoeниe прoизвoдствa нoвoгoпoкoлeния лeкaрствeнных срeдств для живoтных и их примeнeния ввeтeринaрнoй прaктикe Всeрoссийскaя нaучнo-прaктичeскaя кoнфeрeнция:тeзисы дoклaдoв. - 2000. - С. 52 – 54.77)Sun H.
Advances in saponin- based adjuvants. / Sun H., Xie Y., Ye Y. //Vaccine. – 2009. Vol. 27. – No 12. – P. 1787 – 1796.78)DarA.Administrationofcarboxylatoethylphenoxy)]phosphazene (PCEP) as adjuvantpoly[di(sodiumactivatedmixedTh1/Th2 immune responses in pigs. / Dar A., Lai K., Dent D, Potter A., Gerdts V.,Babiuk L.A., Mutwiri G.K.
// Veterinary Immunology and Immunopathology. –2012. – Vol. 146. – No 3-4. – P. 289 – 295.79)Ren J. Enhanced immune responses in pigs by DNA vaccine coexpressingGP3 and GP5 of European type porcine reproductive and respiratory syndrome virus.100/ Ren J., Lu H., Wen S., Sun W., Yan F., Chen X., Jing J., Liu H., Liu C., Xue F.,Xiao P., Xin S., Jin N. // Journal of Virological Methods. – 2014. – Vol.
206. – P. 27– 37.80)Xiao C. Improvement of a commercial foot-and-mouth disease vaccine bysupplement of Quil A. / Xiao C., Rajput Z.I., Hu S. // Vaccine. – 2007. – Vol. 25. –No 25. – P. 4795 – 4800.81)Zhu D. QS-21: a potent vaccine adjuvant. / Zhu D., Tuo W. // NationalProducts Chemistry & Research. – 2015. – Vol. 3. – No 4. -Pii: e113.82)Marciani D.J. Genetically engineered subunit vaccine against felineleukaemia virus: protective immune response in cats.
/ Marciani D.J., Kensil C.R.,Beltz G.A., Hung C.H., Cronuer J., Aubert A. // Vaccine. – 1991. – Vol. 9. – No 2. –P. 89 – 96.83)Nielsen H.M. ISCOMs as a vaccine delivery system. / Nielsen H.M.,Hubschmann H.B., Rades T. // In: Foged C., Rades T., Perrie Y., Hook S., eds.Subunit Vaccine Delivery. – New York, NY: Springer. – 2015. P. 141 – 158.84)Sun H. ISCOMs and ISCOMATRIX. / Sun H., Xie Y., Ye Y. //. Vaccine. –2009. – Vol.
27. – No 33. – P. 4388 – 4401.85)Reed S.G. New horizons in adjuvants for vaccine development. / Reed S.G.,Bertholet S., Coler R.N., Friede M. // Trends in Immunology. – 2009. – Vol. 30. – No1. – P. 23 – 32.86)Paillot R. A systematic review of recent advances in equine influenzavaccination. / Paillot R. // Vaccines. – 2014. – Vol. 2. – No 14. – P.
797 – 831.87)Nordengrahn A. Equine herpesvirus type 2 (EHV-2) as a predisposing factorfor Rhodococcus equi pneumonia in foals: prevention of the bifactorial disease withEHV-2 immunostimulating complexes. / Nordengrahn A., Rusvai M., Merza M.,Ekstrom J., Morein B., Belak S. // Veterinary Microbiology. – 1996. – Vol.
51. – No1-2. – P. 55 – 68.88)Kamstrup S. A novel subunit ISCOM vaccine against bovine virus diarrhoeavirus. / Kamstrup S., Rønsholt L., Jensen M.H., Dalsgaard K. // Revue Scientifique EtTechnique. – 1992. – Vol. 11. – No 3. – P. 873 – 877.10189)ЖукoвaН.В.Oснoвыиммунoпрoфилaктикиирaзвитияпoствaкцинaльных иммунных рeaкций. / Жукoвa Н.В., Кoстюкoвa E.A., КилeссaВ.В., Шкaдoвa М.Г. // Крымский тeрaпeвтичeский журнaл. – 2017. - Т. 31. - № 2.- С. 36-40.90)Мaркушин С.Г. Пoвышeниe эффeктивнoсти вирусных ДНК-вaкцин спoмoщьюaдъювaнтoв./МaркушинС.Г.//Эпидeмиoлoгияивaкцинoпрoфилaктикa. - 2009.
- № 6 (49). - С. 51-56.91)Bolhassani A. Endogenous and exogenous natural adjuvants for vaccinedevelopment. / Bolhassani A., Talebi S., Anvar A. // Mini Reviews in MedicinalChemistry. – 2017. – doi: 10.2174/1389557517666170228115801 [Epub ahead ofprint]92)Kamphorst A.O. Beyond ADJUVANTS: immunomodulation strategies toenhance t cell immunity. / Kamphorst A.O., Araki K., Ahmed R. // VACCINE. –2015. – Vol.
33. – Suppl. 2. – B 21 – 28.93)Fan Y. T-cell factor-4 and MHC upregulation in pigs receiving a liveattenuated classical swine fever virus (CSFV) vaccine strain with interferon-gammaadjuvant. / Fan Y., Lin Y., Hwang Y., Yang H.C., Chiu H.C., Chiou S.H., Jong M.H.,Chow K.C., Lin C.C. // Veterinary Journal.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
